SELLAS Life Sciences (SLS) Income from Continuing Operations (2010 - 2026)
SELLAS Life Sciences (SLS) reported Income from Continuing Operations of 8407000.0 for Q1 2026, down 44.62% year-over-year from 15181699.6 in Q1 2025, and down 9.78% on a QoQ basis from 7658000.0 in Q4 2025.
SELLAS Life Sciences (SLS) has 15 years of Income from Continuing Operations data on file, last reported at 8407000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 44.62% year-over-year to 8407000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29457000.0 (down 8.59% YoY) and the FY2025 annual result came in at 26863000.0, up 13.01% from the prior year.
- Income from Continuing Operations fell to 8407000.0 in Q1 2026 per SLS's latest filing, from 7658000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5813000.0 in Q1 2025 and bottomed at 16735000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 8136000.0 (2023), against an average of 8566294.12.
- The widest annual swing landed in 2022, when Income from Continuing Operations sank 645.43%; it then soared 39.23% in 2025.
- Tracing SLS's Income from Continuing Operations over 5 years: stood at 9446000.0 in 2022, then gained by 13.87% to 8136000.0 in 2023, then advanced by 17.2% to 6737000.0 in 2024, then slipped by 13.67% to 7658000.0 in 2025, then declined by 9.78% to 8407000.0 in 2026.
- Per Business Quant, the three latest SLS Income from Continuing Operations figures stand at 8407000.0 (Q1 2026), 7658000.0 (Q4 2025), and 6791000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | -8.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.41 Mn |
| Dec 31, 2025 | -7.66 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Dec 31, 2024 | -6.74 Mn |
| Sep 30, 2024 | -7.11 Mn |
| Jun 30, 2024 | -7.47 Mn |
| Mar 31, 2024 | -9.57 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Sep 30, 2023 | -9.27 Mn |
| Jun 30, 2023 | -8.84 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -11.62 Mn |
| Sep 30, 2021 | -6.98 Mn |
| Jun 30, 2021 | -4.45 Mn |
| Mar 31, 2021 | -2.25 Mn |
| Dec 31, 2020 | -4.16 Mn |
| Sep 30, 2020 | -4.49 Mn |
| Jun 30, 2020 | -4.27 Mn |
| Mar 31, 2020 | -4.06 Mn |
| Dec 31, 2017 | -8.65 Mn |
| Sep 30, 2017 | -4.53 Mn |
| Jun 30, 2017 | -5.03 Mn |
| Mar 31, 2017 | -5.09 Mn |
| Dec 31, 2016 | 8.74 Mn |
| Sep 30, 2016 | -6.47 Mn |
| Jun 30, 2016 | -9.29 Mn |
| Mar 31, 2016 | -8.97 Mn |
| Dec 31, 2015 | -7.59 Mn |
| Sep 30, 2015 | -8.64 Mn |
| Jun 30, 2015 | -9.08 Mn |
| Mar 31, 2015 | -8.91 Mn |
| Dec 31, 2014 | -9.69 Mn |
| Sep 30, 2014 | -10.57 Mn |
| Jun 30, 2014 | -16.27 Mn |
| Mar 31, 2014 | -11.85 Mn |
| Dec 31, 2013 | -43.15 Mn |
| Sep 30, 2013 | -9.29 Mn |
| Jun 30, 2013 | -9.60 Mn |
| Mar 31, 2013 | -9.29 Mn |
| Dec 31, 2012 | -4.80 Mn |
| Sep 30, 2012 | -6.26 Mn |
| Jun 30, 2012 | 227,000.00 |
| Mar 31, 2012 | -23.54 Mn |
| Jun 30, 2011 | -4.63 Mn |
| Jun 30, 2010 | -4.75 Mn |